Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Journal of Long-Term Effects of Medical Implants
SJR: 0.332 SNIP: 0.491 CiteScore™: 0.89

ISSN Imprimir: 1050-6934
ISSN En Línea: 1940-4379

Journal of Long-Term Effects of Medical Implants

DOI: 10.1615/JLongTermEffMedImplants.2015012529
pages 253-268

Osteonecrosis of the Hip in Hematologic Disease: A Review of Conditions and Treatment Options

Megan M. Sorich
Rowan University School of Osteopathic Medicine, Stratford, New Jersey
Jeffery J. Cherian
Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland
Mark J. McElroy
Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland
Samik Banerjee
Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, MD; Department of Orthopaedic Surgery, Johns Hopkins Bayview Medical Center, Johns Hopkins University, Baltimore, MD
Lynne C. Jones
Johns Hopkins University, Center for Osteonecrosis Research and Education, Baltimore, Maryland
Caterina P. Minniti
9200 Rockville Pike, Clinical Center 5-5140, Bethesda, Maryland
Michael A. Mont
Center for Joint Preservation and Replacement, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland

SINOPSIS

Osteonecrosis of the hip can lead to advanced arthritis in typically young patients. Hematologic disorders comprise one group of potential causes. These include sickle cell anemia, hemophilia, aplastic anemia, thalassemia, and acute lymphoblastic leukemia. Depending on the stage of disease, treatment options include non-operative management, joint-preserving procedures (percutaneous drilling, core decompression, and vascularized or non-vascularized bone grafting), and joint arthroplasty (resurfacing arthroplasty and THA). Numerous small studies have investigated the efficacy of these options in patients who have specific hematologic disorders. Therefore, this report provides a comprehensive review of the osteonecrosis treatment options and results across the spectrum of patients who have various hematologic disorders.